Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.64 |
| ▸ | PDE6C | P51160 | 2/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.59 |
| ▸ | PDE6A | P16499 | 1/20 | 0.59 |
| ▸ | PDE6G | P18545 | 1/20 | 0.59 |
| ▸ | PDE6B | P35913 | 1/20 | 0.59 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.59 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313114 | 0.97 | PDE5A (0.60) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6312725 | 0.94 | PDE5A (0.71) | PDE5APDE3BPDE3A | |
| SCHEMBL6306242 | 0.94 | PDE5A (0.65) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6304753 | 0.92 | PDE5A (0.55) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6305495 | 0.92 | PDE5A (0.59) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6309324 | 0.92 | PDE5A (0.66) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6306537 | 0.91 | PDE5A (0.68) | PDE5APDE3BPDE3A | |
| SCHEMBL6306565 | 0.90 | PDE5A (0.61) | PDE5APDE6CPDE11APDE3BPDE3A | |
| SCHEMBL6311832 | 0.90 | PDE5A (0.60) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL6309100 | 0.88 | PDE5A (0.63) | PDE5APDE6CPDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943253-B2 | 6-phenylpyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-09-13 | — | — | US | claimed |
| EP-1286997-B1 | 6-PHENYLPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-08-18 | — | — | EP | claimed |
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PARALLEL WIRELESS, INC. | 2003-12-18 | — | — | US | claimed |
| EP-1286997-A1 | 6-PHENYLPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2003-03-05 | — | — | EP | claimed |
| WO-2001094350-A1 | 6-PHENYLPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-12-13 | — | — | WO | claimed |
| US-6943253-B2 | 6-phenylpyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-09-13 | — | — | US | disclosed |
| EP-1286997-B1 | 6-PHENYLPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-08-18 | — | — | EP | disclosed |
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PARALLEL WIRELESS, INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 34/4885PDE6D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.